Roche Lung Cancer Drug Shows Promise in Phase 3 Trial
September 01 2023 - 1:04AM
Dow Jones News
By David Sachs
Roche said Friday that its Alecensa drug demonstrated the
ability to reduce recurrence of lung cancer for patients in the
early stage of the disease.
The Swiss pharmaceutical company said the results, from a Phase
3 study of 257 people which compared the treatment with
platinum-based chemotherapy, met its primary goal of disease-free
survival in people with early-stage non-small cell lung cancer.
About half of people with this type of lung cancer experience a
recurrence of the disease after surgery, Roche said.
Roche said that it found no unexpected safety issues and will
submit the data to global health authorities.
Write to David Sachs at david.sachs@wsj.com
(END) Dow Jones Newswires
September 01, 2023 01:49 ET (05:49 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Dec 2024 to Jan 2025
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Jan 2024 to Jan 2025
